PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.

India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.

Bachem partners with Eli Lilly on oligonucleotide-based APIs

Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology

Leading inhalation APIs expert Inke to triple production capacity

To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs

Equipment shortage and overpriced APIs pinch the pharma industry

A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges

Fermenta granted process patent for plant-based Vitamin D3

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL

From Policy to Practice: How India’s Pharmaceutical Industry is Being Shaped by the PLI Scheme – by Vikram Aditya Sehgal, Director – Finance, Centrient India

The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent

Sigachi begins construction work for MCC capacity expansion at Dahej

With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA

Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business

His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors